CIK 0001806952
- Non-accelerated filer
- Smaller reporting company
Lyell Immunopharma, Inc.
Sign in to watch- Ticker
- LYEL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833006753
- Phone
- +1 650-695-0677
- Business address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $49,999,983
- in 2 filings
- Open-market sales, last 90 days
- $28,757
- in 6 filings
Net +$49,971,226. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-08 | Bishop Hans Edgar Director | Grant or award · Option (right to buy) | +65,000 | 65,000 | ||
| 2022-06-08 | FRIEDMAN CATHY Director | Grant or award · Option (right to buy) | +65,000 | 65,000 | ||
| 2022-06-08 | Klausner Richard Director | Grant or award · Option (right to buy) | +65,000 | 65,000 | ||
| 2022-03-16 | Turner Heather D Chief General Counsel | Grant or award · Option (right to buy) | +300,000 | 300,000 | ||
| 2022-03-16 | Newton Charles W. Chief Financial Officer | Grant or award · Option (right to buy) | +500,000 | 500,000 | ||
| 2022-03-16 | Homans Elizabeth Chief Executive Officer | Grant or award · Option (right to buy) | +1,479,500 | 1,479,500 | ||
| 2022-03-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Option (right to buy) | +700,000 | 700,000 | ||
| 2022-02-23 | Bishop Hans Edgar Director | Exercise or conversion | +993,428 | $0.10 | $99K | 4,540,234 |
| 2022-02-23 | Bishop Hans Edgar Director | Exercise or conversion · Option (right to buy) | −993,428 | 169,610 | ||
| 2022-02-11 | Lee Gary K. Chief Scientific Officer | Grant or award · Option (right to buy) | +800,000 | 800,000 | ||
| 2021-12-14 | FRIEDMAN CATHY Director | Other disposition | −3,765,842 | 0 | ||
| 2021-12-14 | FRIEDMAN CATHY Director | Other acquisition | +218,722 | 236,370 | ||
| 2021-09-13 | Homans Elizabeth Chief Executive Officer | Grant or award · Option (right to buy) | +1,370,469 | 1,370,469 | ||
| 2021-06-21 | GLAXOSMITHKLINE PLC 10% owner | Conversion | +30,253,189 | 30,253,189 | ||
| 2021-06-21 | GLAXOSMITHKLINE PLC 10% owner | Conversion · Series AA Preferred Stock | −30,253,189 | 0 | ||
| 2021-06-21 | NELSEN ROBERT Director | Conversion | +18,206,358 | 18,206,358 | ||
| 2021-06-21 | NELSEN ROBERT Director | Conversion | +18,206,358 | 18,206,358 | ||
| 2021-06-21 | NELSEN ROBERT Director | Conversion · Series A Convertible Preferred Stock | −17,771,216 | 0 | ||
| 2021-06-21 | NELSEN ROBERT Director | Conversion · Series A Convertible Preferred Stock | −17,771,216 | 0 | ||
| 2021-06-21 | NELSEN ROBERT Director | Conversion · Series C Convertible Preferred Stock | −435,142 | 0 |
Page 10 of 11 · 214 trades